-

Partnership for Safe Medicines Releases Action Plan to Protect Patients from Unapproved Knockoff GLP-1s

Plan serves as policy roadmap to strengthen America’s gold standard patient safety system

WASHINGTON--(BUSINESS WIRE)--The Partnership for Safe Medicines today published a report outlining solutions to protect patients from the risks of a growing compounded GLP-1 marketplace. A Call to Action: Restoring and Strengthening America’s Patient Safety System serves as a detailed plan for policymakers and regulators to uphold the gold standard system that protects Americans from untested and unsafe medicines.

Today, emboldened by a lack of regulatory enforcement, telehealth companies and compounding entities are producing and marketing large volumes of unapproved compounded medications. These deceptively advertised compounded drugs carry significant risks for patients because they exist outside of the FDA’s rigorous review and approval system and they raise concerns about transparency and informed decision-making. PSM’s new report is a call to action for stricter enforcement of compounding violations, foreign imports and deceptive marketing and the development and implementation of new laws and policies that will help keep patients safe.

"The availability of unauthorized GLP-1 knockoffs risks the safety of millions of Americans who do not recognize the dangers of these drugs,” PSM Executive Director Shabbir Imber Safdar said. “From dosing errors to quality and sterility concerns, too many Americans have already suffered at the hands of an industry that continues to pursue commercial interests at the expense of unsuspecting patients. We’re pleased to share this action plan as a guide for policymakers to uphold America's safety standards, empower the FDA to hold bad actors to account, and protect patients from substandard and dangerous medications.”

PSM invites partners, lawmakers, and agency leaders to join them in building on initial steps taken this year and putting the recommendations into action.

About the Partnership for Safe Medicines

The Partnership for Safe Medicines (PSM) is a public health group comprised of non-profit organizations that handle medicine from the factory floor to the patient and are committed to the safety of prescription drugs. To learn more, visit www.safemedicines.org.

Contacts

editors@safemedicines.org

Industry:

Partnership for Safe Medicines

Release Versions
English

Contacts

editors@safemedicines.org

More News From Partnership for Safe Medicines

New Report Reveals Illegal Ingredients for Knockoff Weight Loss Drugs Flooding into U.S. from Foreign Sources, Endangering Patient Safety

WASHINGTON--(BUSINESS WIRE)--The Partnership for Safe Medicines today released a new report that found suspicious, unauthorized, and illegal ingredients for popular diabetes and obesity injectables (commonly known as weight loss drugs) are flooding into the U.S. from foreign sources despite U.S. laws forbidding them from coming through the border. The U.S. Food and Drug Administration (FDA) has warned against drug compounders’ use of unauthorized bulk drug ingredients, semaglutide and tirzepati...

More Than 90% of Likely Voters Are Concerned About Safety and Regulation of Compounded Weight Loss Drugs

WASHINGTON--(BUSINESS WIRE)--Today, the Partnership for Safe Medicines unveiled the results of a national public opinion poll that shows more than 90% of likely voters are concerned about the safety, regulation, and efficacy of compounded medications for diabetes and obesity (or weight loss). Ninety percent say the FDA should use their existing authority to ensure these compounded weight loss drugs are safe. Compounded medicines serve an important role in the U.S. healthcare system when used to...

Partnership for Safe Medicines Condemns the Weakening of the U.S. Drug Supply through Canadian Drug Importation

WASHINGTON--(BUSINESS WIRE)--Shabbir Safdar, executive director of the Partnership for Safe Medicines, released the following statement in response to the U.S. Food and Drug Administration’s final decision to approve Florida’s Canadian drug importation plan. “The United States government’s decision to approve Florida’s Canadian drug importation plan weakens our nation’s safe drug supply, putting American patients at risk. This decision breaks our closed loop system and opens the door to counter...
Back to Newsroom